Estradiol in micellar nanoparticles: The efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms

Menopause

Volumn 13, Issue 2, 2006, Pages 222-231

  Simon, James A ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Women's Health Research Center   (United States)

^c NONE   (United States)

Author keywords

17 Estradiol; Menopause; Micellar nanoparticle; Topical; Vasomotor symptoms

Indexed keywords

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; EMULSIONS; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MICELLES; MIDDLE AGED; NANOPARTICLES; POSTMENOPAUSE; TIME FACTORS; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

EID: 33646756599     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000174096.56652.4f     Document Type: Article

References (26)

1. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Mad 1999;130:545-553.
2. von Holst T, Salbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas 2000;34:143-153.
3. Osteoporosis prevention diagnosis, and therapy. NIH Consens Statement 2000;17:1-45.
4. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
5. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-188.
6. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;291:1610-1620.
7. Nelson HD. Postmenopausal estrogen for treatment of hot flashes: clinical applications. JAMA 2004;291:1621-1625.
8. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol. Menopause 2000;7:310-317.
9. Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562-567.
10. Buckler H, Al-Azzawi F. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. Br J Obstet Gynaecol 2003;110:753-759.
11. Bacchi-Modena A, Bolis P, Campagnoli C, et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27:285-292.
12. Archer DF. Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003;10:516-521.
13. Järvinen A, Bäckström AC, Elfström C, Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Maturitas 2001;38:189-196.
14. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-1676.
15. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3078.
16. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687-2693.
17. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Venous thromboembolic disease. Obstet Gynecol 2004;104:118S-127S.
18. Cedars MI, Judd HL. Nonoral routes of estrogen administration. Obstet Gynecol Clin North Am 1987;14:269-298.
19. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol- norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498-503.
20. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001;8:328-332.
21. Wright DC, inventer; Novavax Inc. assignee. Micellar nanoparticles. US patent 5 629 021; May 13, 1997.
22. Boxenbaum H, Muenz LR, and the Estrasorb Study Group. Pharmacokinetics of Estrasorb™, a topical lotion for treatment of postmenopausal vasomotor symptoms [Abstract]. J Soc Gynecol Invest 2002;9(Suppl):238A. Abstract 533.
23. Wu CH, Lundy LE. Radioimmunoassay of plasma estrogens. Steroids 1971;18:91-111.
24. Good WR, John VA, Ramirez M, Higgins JE. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group. Clin Ther 1996;18:1093-1105.
25. Studd J, Pornel B, Marton I, et al, Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet 1999;353:1574-1578. Published erratum appears in Lancet 1999; 234:780.
26. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731.